Ultragenyx Pharmaceutical RARE Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $672.71M+20.1% | $560M+29.0% | $434M+19.5% | $363.33M+3.4% | ||
| $750.23M+7.5% | $698M+7.7% | $648M-8.2% | $705.79M+42.0% | ||
| $348.2M+8.5% | $321M+3.5% | $310M+11.5% | $278.14M+26.4% | ||
| -$535.06M+0.2% | -$536M+5.8% | -$569M+12.3% | -$648.92M-70.0% | ||
| -79.5%+16.2pp | -95.7%+35.4pp | -131.1%+47.5pp | -178.6%-70.0pp | ||
| -$571.23M-0.7% | -$567M+6.9% | -$609M+13.2% | -$701.73M-54.9% | ||
| $3.69M+84.5% | $2M+200% | -$2M— | —— | ||
| -$574.92M-1.0% | -$569M+6.3% | -$607M+14.2% | -$707.42M-55.8% | ||
| -85.5%+16.1pp | -101.6%+38.3pp | -139.9%+54.8pp | -194.7%-65.5pp | ||
| -$5.83+7.9% | -$6.33+23.3% | -$8.25+18.4% | -$10.11-50.7% | ||
| -$500.06M0.0% | -$500M+7.9% | -$543M+13.9% | -$630.7M-71.2% | ||
| -74.3%+15.0pp | -89.3%+35.8pp | -125.1%+48.5pp | -173.6%-68.7pp | ||
| -$535.06M+0.2% | -$536M+5.8% | -$569M+12.3% | -$648.92M-70.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ultragenyx Pharmaceutical's revenue?
- Ultragenyx Pharmaceutical (RARE) generated $669.7M in revenue over the trailing twelve months, up 13.5% year over year.
- Is Ultragenyx Pharmaceutical profitable?
- Ultragenyx Pharmaceutical is not currently profitable: it reported a net loss of $608.9M over the trailing twelve months, a -90.9% net margin.
- What are Ultragenyx Pharmaceutical's profit margins?
- Gross margin is 97.2% and operating margin is -83.8%, with a -90.9% net margin.
- What is Ultragenyx Pharmaceutical's earnings per share?
- Ultragenyx Pharmaceutical's diluted EPS over the trailing twelve months is $-6.10.
- Where does Ultragenyx Pharmaceutical's income statement data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
